Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
VNRX 
Volitionrx Ltd (VNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: VNRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.94
1 Year Target Price $2.94
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.26% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 78.30M USD | Price to earnings Ratio - | 1Y Target Price 2.94 |
Price to earnings Ratio - | 1Y Target Price 2.94 | ||
Volume (30-day avg) 6 | Beta 1.06 | 52 Weeks Range 0.40 - 0.94 | Updated Date 06/30/2025 |
52 Weeks Range 0.40 - 0.94 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.27 |
Earnings Date
Report Date 2025-07-02 | When Before Market | Estimate -0.11 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2241.09% |
Management Effectiveness
Return on Assets (TTM) -108.04% | Return on Equity (TTM) -730.06% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 83065807 | Price to Sales(TTM) 59.84 |
Enterprise Value 83065807 | Price to Sales(TTM) 59.84 | ||
Enterprise Value to Revenue 63.49 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 103023000 | Shares Floating 71774869 |
Shares Outstanding 103023000 | Shares Floating 71774869 | ||
Percent Insiders 18.46 | Percent Institutions 20.39 |
Analyst Ratings
Rating 3 | Target Price 2.94 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Volitionrx Ltd
Company Overview
History and Background
VolitionRx Limited is a multi-national epigenetics company developing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer. It was founded in 2010.
Core Business Areas
- Nu.Q Platform Development: Focuses on research, development, and commercialization of Nu.Q assays based on its Nucleosomics technology platform for cancer and other diseases. This includes developing and validating diagnostic and monitoring blood tests.
Leadership and Structure
Cameron Reynolds is the current CEO. The company has a Board of Directors and various management teams overseeing research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Nu.Q Assays: Volition's primary product is the Nu.Q assay, a blood test designed to detect and measure circulating nucleosomes, which are indicative of disease states like cancer. Market share data is limited, as the technology is relatively new and not yet widely adopted. Key competitors in cancer diagnostics include Roche, Abbott, and Exact Sciences. Revenue generation is still in its early stages.
Market Dynamics
Industry Overview
The cancer diagnostics market is experiencing significant growth, driven by increasing incidence rates, technological advancements in liquid biopsies, and a growing demand for non-invasive diagnostic methods.
Positioning
VolitionRx is positioned as a player in the liquid biopsy space, offering a novel approach based on nucleosome detection. Its competitive advantage lies in its platform's potential for cost-effectiveness and broad applicability across various cancers.
Total Addressable Market (TAM)
The global cancer diagnostics market is projected to reach billions of dollars. VolitionRx is aiming to capture a portion of this market with its Nu.Q technology, focusing initially on specific cancer types and expanding its portfolio over time.
Upturn SWOT Analysis
Strengths
- Novel Nucleosomics technology
- Potential for cost-effective diagnostics
- Broad applicability across various cancers
- Strong patent portfolio
Weaknesses
- Limited commercial traction
- High reliance on research and development
- Significant cash burn rate
- Dependence on partnerships for commercialization
Opportunities
- Expansion of Nu.Q platform to new disease areas
- Partnerships with major diagnostic companies
- Positive clinical trial results
- Increasing adoption of liquid biopsies
Threats
- Competition from established diagnostic companies
- Regulatory hurdles
- Technological advancements in competing liquid biopsy technologies
- Market acceptance of Nu.Q technology
Competitors and Market Share
Key Competitors
- Roche (RHHBY)
- Exact Sciences (EXAS)
- Guardant Health (GH)
Competitive Landscape
VolitionRx faces intense competition from established players with greater resources and broader product portfolios. Its success will depend on demonstrating the clinical utility and cost-effectiveness of its Nu.Q technology.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by research and development progress and strategic partnerships.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of Nu.Q assays.
Recent Initiatives: Recent initiatives include expanding clinical trials, securing regulatory approvals in specific markets, and forging partnerships with diagnostic companies.
Summary
VolitionRx is a speculative investment with potential in the liquid biopsy market. Its Nu.Q technology offers a novel approach to cancer diagnostics, but the company faces significant challenges in terms of commercialization and competition. Successful clinical trials and strategic partnerships are crucial for its future growth. The company needs to carefully manage cash flow and secure additional funding to sustain its operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Volitionrx Ltd
Exchange NYSE MKT | Headquaters Henderson, NV, United States | ||
IPO Launch date 2007-04-25 | Founder, CEO, President & Director Mr. Cameron Reynolds MBA | ||
Sector Healthcare | Industry Medical Devices | Full time employees 82 | Website https://www.volition.com |
Full time employees 82 | Website https://www.volition.com | ||
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and diseases associated with NETosis such as sepsis in the United States and internationally. It offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis such as sepsis; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.